Table 2.
Sample characteristics of the US population-based sample (n = 1143) and the Swiss clinic-based sample (n = 2481)
| Variables included in BCRAT and BOADICEA models and in ML algorithms | US population-based sample n = 1143 | Swiss clinic-based sample n = 2481 |
|---|---|---|
| Age (range) | 50.86 ± 6.22 (35–64) | 50.78 ± 12.77 (13–89) |
| Age at menarche (range) | 12.56 ± 1.54 (8–18) | 12.91 ± 1.59 (8–18) |
| Age at first live birth (range) | 24.29 ± 5.62 (13–42) | 24.13 ± 5.72 (15–48) |
| Number of biopsies (n = 847) | 1.20 ± 1.21 | – |
| Atypical hyperplasia | 14 (1.65%) | – |
| Breast cancer | 850 (74.37%) | 886 (35.71%) |
| First-ductal carcinoma in situ (DCIS) | 434 (51.06%) | 50 (5.64%) |
| First-invasive breast cancer | 404 (47.52%) | 807 (91.08%) |
| First-breast cancer age onset (range) | 40.03 ± 4.79 (26–54) | 46.07 ± 10.69 (22–84) |
| Bilateral breast cancer | 4 (0.47%) | 160 (18.06%) |
| Estrogen receptor (ER) positive | – | 618 (69.75%) |
| Progesterone receptor (PR) positive | – | 561 (63.32%) |
| Pancreatic cancer | – | 13 (0.52%) |
| Pancreatic cancer age onset (range) | 55.10 ± 9.35 (36–75) | |
| Ovarian cancer | 9 (0.79%) | 133 (5.36%) |
| Ovarian cancer age onset (range) | 45.83 ± 5.00 (36–50) | 56.44 ± 13.16 (21–85) |
| Having also breast cancer | 4 | 20 |
| Ethnicity (% Black) | 401 (35.08%) | 71 (2.86%) |
| Ashkenazi Jewish origin | 12 (1.05%) | 65 (2.29%) |
| Number of first-degree relatives with breast cancer | 0.98 ± 1.05 | 0.25 ± 0.55 |
| Breast cancer patients | 0.81 ± 1.05 | – |
| Relatives of breast cancer patients | 1.49 ± 0.88 | – |
| BRCA1 or BRCA2 germline mutations | 32 (2.79%) 235 tested | 209 (8.42%) 1052 tested |
– Data not available